Investigating the effect of Quince fruit product for treatment nausea and vomiting of pregnancy.

Comparison of the effectiveness of "Quince" (CydoniaOblonga) product and vitamin B6 for treatment nausea and vomiting of pregnancy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231030059899N1

Enrollment

120

Registered

2024-03-14

Start date

2020-07-22

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperemesis Gravidarum. Hyperemesis gravidarum, mild or unspecified, starting before the end of the 22nd week of gestation

Interventions

Intervention 1: Control group: patients were given vitamin B6 tablets. Intervention 2: Intervention group: And it was given Quince product to the intervention.

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Single pregnant woman with a healthy fetus With a gestational age of 6 to 16 weeks With mild to moderate nausea and vomiting Not taking anti emetic medication in the last 48 hours No history of specific disease Literacy for reading and writing

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of nausea and vomiting. Timepoint: Measure improvement over two weeks on days 4 and 11. Method of measurement: Measurement of improvement based on PUQE-24 and severity based on VAS scoring system.;Duration of nausea and vomiting. Timepoint: Measure improvement over two weeks on days 4 and 11. Method of measurement: Measurement of improvement based on PUQE-24 and severity based on VAS scoring system.;Frequency of vomiting. Timepoint: Measure improvement over two weeks on days 4 and 11. Method of measurement: Measurement of improvement based on PUQE-24 and severity based on VAS scoring system.;Frequency of retching. Timepoint: Measure improvement over two weeks on days 4 and 11. Method of measurement: Measurement of improvement based on PUQE-24 and severity based on VAS scoring system.;Amount of sleep. Timepoint: Measure improvement over two weeks on days 4 and 11. Method of measurement: Measurement of improvement based on PUQE-24 and severity based on VAS scoring system.;Appetite. Timepoint: Measure improvement over two weeks on days 4 and 11. Method of measurement: Measurement of improvement based on PUQE-24 and severity based on VAS scoring system.	—

Measure

Time frame

Severity of nausea and vomiting. Timepoint: Measure improvement over two weeks on days 4 and 11. Method of measurement: Measurement of improvement based on PUQE-24 and severity based on VAS scoring system.;Duration of nausea and vomiting. Timepoint: Measure improvement over two weeks on days 4 and 11. Method of measurement: Measurement of improvement based on PUQE-24 and severity based on VAS scoring system.;Frequency of vomiting. Timepoint: Measure improvement over two weeks on days 4 and 11. Method of measurement: Measurement of improvement based on PUQE-24 and severity based on VAS scoring system.;Frequency of retching. Timepoint: Measure improvement over two weeks on days 4 and 11. Method of measurement: Measurement of improvement based on PUQE-24 and severity based on VAS scoring system.;Amount of sleep. Timepoint: Measure improvement over two weeks on days 4 and 11. Method of measurement: Measurement of improvement based on PUQE-24 and severity based on VAS scoring system.;Appetite. Timepoint: Measure improvement over two weeks on days 4 and 11. Method of measurement: Measurement of improvement based on PUQE-24 and severity based on VAS scoring system.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Torkamani

Shahid Beheshti University of Medical Sciences

zahra.torkamani0@yahoo.com+98 21 7738 3261

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026